Y-mAbs Therapeutics, Inc. (YMAB): Price and Financial Metrics

Y-mAbs Therapeutics, Inc. (YMAB): $10.02

0.14 (+1.42%)

POWR Rating

Component Grades














  • YMAB scores best on the Value dimension, with a Value rank ahead of 71.17% of US stocks.
  • The strongest trend for YMAB is in Stability, which has been heading down over the past 179 days.
  • YMAB ranks lowest in Stability; there it ranks in the 3rd percentile.

YMAB Stock Summary

  • For YMAB, its debt to operating expenses ratio is greater than that reported by merely 7.42% of US equities we're observing.
  • YMAB's price/sales ratio is 15.81; that's higher than the P/S ratio of 90.98% of US stocks.
  • In terms of volatility of its share price, YMAB is more volatile than 95.06% of stocks we're observing.
  • Stocks that are quantitatively similar to YMAB, based on their financial statements, market capitalization, and price volatility, are TARS, BCDA, ADAP, CAPR, and STRO.
  • YMAB's SEC filings can be seen here. And to visit Y-mAbs Therapeutics Inc's official web site, go to www.ymabs.com.

YMAB Valuation Summary

  • In comparison to the median Healthcare stock, YMAB's EV/EBIT ratio is 189.76% lower, now standing at -26.3.
  • YMAB's price/sales ratio has moved NA NA over the prior 36 months.
  • YMAB's EV/EBIT ratio has moved down 3.2 over the prior 36 months.

Below are key valuation metrics over time for YMAB.

Stock Date P/S P/B P/E EV/EBIT
YMAB 2021-08-31 36.2 5.7 -31.7 -26.3
YMAB 2021-08-30 35.1 5.6 -30.8 -25.3
YMAB 2021-08-27 35.0 5.5 -30.7 -25.3
YMAB 2021-08-26 33.6 5.3 -29.4 -24.0
YMAB 2021-08-25 33.9 5.4 -29.8 -24.3
YMAB 2021-08-24 33.9 5.4 -29.7 -24.2

YMAB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • YMAB has a Quality Grade of C, ranking ahead of 28.99% of graded US stocks.
  • YMAB's asset turnover comes in at 0.183 -- ranking 204th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows YMAB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.183 0.992 -10.948
2021-03-31 0.146 0.996 -77.742
2020-12-31 0.130 1.000 45.423
2020-09-30 0.000 NA 33.823
2020-06-30 0.000 NA 26.410
2020-03-31 0.000 NA 20.272

YMAB Price Target

For more insight on analysts targets of YMAB, see our YMAB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $55.00 Average Broker Recommendation 1.36 (Strong Buy)

YMAB Stock Price Chart Interactive Chart >

Price chart for YMAB

YMAB Price/Volume Stats

Current price $10.02 52-week high $39.82
Prev. close $9.88 52-week low $6.50
Day low $9.75 Volume 376,600
Day high $10.50 Avg. volume 680,187
50-day MA $11.00 Dividend yield N/A
200-day MA $17.85 Market Cap 438.01M

Y-mAbs Therapeutics, Inc. (YMAB) Company Bio

Y-mAbs Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody therapeutic products for cancer treatment in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. The company has a license and research collaboration agreement with Memorial Sloan-Kettering Cancer Center. Y-mAbs Therapeutics, Inc. was founded in 2015 and is based in New York, New York.

YMAB Latest News Stream

Event/Time News Detail
Loading, please wait...

YMAB Latest Social Stream

Loading social stream, please wait...

View Full YMAB Social Stream

Latest YMAB News From Around the Web

Below are the latest news stories about Y-mAbs Therapeutics Inc that investors may wish to consider to help them evaluate YMAB as an investment opportunity.

YmAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Misses Revenue Estimates

YmAbs Therapeutics, Inc. (YMAB) delivered earnings and revenue surprises of -19.72% and 7.46%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments

Announced completion of pre-BLA meeting with the FDA for omburtamab BLA resubmission expected by the end of first quarter 2022 DANYELZA® adoption drives sequential revenue increase Completed IND submission to the FDA for first SADA construct Appointed Sue Smith as Chief Commercial Officer Strong cash position with $181.6 million as of December 31, 2021, providing runway through the end of 2023 The Company will host a conference call on Friday, February 25, 2022, at 9 a.m. EST NEW YORK, Feb. 24,

Yahoo | February 24, 2022

Y-mAbs to Announce 2021 Financial and Operating Results on February 24, 2022

NEW YORK, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the year ended December 31, 2021 on Thursday, February 24, 2022, after the close of the U.S. financial markets. The announcement will be followed by a conference call and webcast with the investment community on Friday, February 25, 2022, at 9 a.m. ET. Participating on the call from Y-mAbs will be Thomas Gad, founder, Chairman and President; Dr. Claus Moller, Chief Executive Officer; and Bo Kruse, Chief Financial Officer.

GlobeNewswire | February 17, 2022

Earnings Preview: YmAbs Therapeutics, Inc. (YMAB) Q4 Earnings Expected to Decline

YmAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA

Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.

Yahoo | February 14, 2022

Read More 'YMAB' Stories Here

YMAB Price Returns

1-mo -14.58%
3-mo 28.96%
6-mo -42.01%
1-year -71.89%
3-year -53.16%
5-year N/A
YTD -38.19%
2021 -67.26%
2020 58.43%
2019 53.64%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5222 seconds.